MX2023007062A - Metodos de tratamiento de la diabetes. - Google Patents
Metodos de tratamiento de la diabetes.Info
- Publication number
- MX2023007062A MX2023007062A MX2023007062A MX2023007062A MX2023007062A MX 2023007062 A MX2023007062 A MX 2023007062A MX 2023007062 A MX2023007062 A MX 2023007062A MX 2023007062 A MX2023007062 A MX 2023007062A MX 2023007062 A MX2023007062 A MX 2023007062A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- treating diabetes
- weekly
- dosing
- bif
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 102000016261 Long-Acting Insulin Human genes 0.000 abstract 1
- 108010092217 Long-Acting Insulin Proteins 0.000 abstract 1
- 229940100066 Long-acting insulin Drugs 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 230000003442 weekly effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/3159—Dose expelling manners
- A61M5/31591—Single dose, i.e. individually set dose administered only once from the same medicament reservoir, e.g. including single stroke limiting means
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
En el presente documento se describen dosis fijas y regímenes de dosificación para agonistas de receptor de insulina de acción prolongada adecuados para dosificación una vez por semana, tales como insulina basal-Fc (BIF) semanal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063125165P | 2020-12-14 | 2020-12-14 | |
| PCT/US2021/063235 WO2022132712A1 (en) | 2020-12-14 | 2021-12-14 | Methods of treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007062A true MX2023007062A (es) | 2023-06-23 |
Family
ID=79287778
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007062A MX2023007062A (es) | 2020-12-14 | 2021-12-14 | Metodos de tratamiento de la diabetes. |
| MX2023007064A MX2023007064A (es) | 2020-12-14 | 2021-12-14 | Metodos para tratar la diabetes. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007064A MX2023007064A (es) | 2020-12-14 | 2021-12-14 | Metodos para tratar la diabetes. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20240082363A1 (es) |
| EP (2) | EP4259185A1 (es) |
| JP (2) | JP2023554358A (es) |
| KR (2) | KR20230118936A (es) |
| CN (2) | CN116710119A (es) |
| AU (2) | AU2021401635A1 (es) |
| CA (2) | CA3202345A1 (es) |
| IL (2) | IL303631A (es) |
| MX (2) | MX2023007062A (es) |
| TW (2) | TW202237175A (es) |
| WO (2) | WO2022132712A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024059480A2 (en) * | 2022-09-12 | 2024-03-21 | Eli Lilly And Company | A gip/glp1 for use in therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2708252T3 (pl) | 2010-03-01 | 2016-01-29 | Lilly Co Eli | Automatyczne urządzenie do iniekcji z mechanizmem opóźniającym zawierające dwufunkcyjny element przemieszczający |
| US20150111820A1 (en) | 2012-07-09 | 2015-04-23 | Novo Nordisk A/S | Novel use of insulin derivatives |
| WO2016001185A1 (en) | 2014-07-02 | 2016-01-07 | Novo Nordisk A/S | Dosage regimen for the treatment of diabetes |
| AR105616A1 (es) * | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
| EP4344738A3 (en) * | 2018-06-29 | 2024-05-22 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| JP2022502467A (ja) * | 2018-10-10 | 2022-01-11 | ノヴォ ノルディスク アー／エス | オリゴマー伸長インスリン−ｆｃコンジュゲートおよびそれらの医学的使用 |
-
2021
- 2021-12-14 TW TW110146786A patent/TW202237175A/zh unknown
- 2021-12-14 IL IL303631A patent/IL303631A/en unknown
- 2021-12-14 CA CA3202345A patent/CA3202345A1/en active Pending
- 2021-12-14 EP EP21840344.2A patent/EP4259185A1/en active Pending
- 2021-12-14 MX MX2023007062A patent/MX2023007062A/es unknown
- 2021-12-14 KR KR1020237023480A patent/KR20230118936A/ko active Search and Examination
- 2021-12-14 EP EP21840748.4A patent/EP4259186A1/en active Pending
- 2021-12-14 AU AU2021401635A patent/AU2021401635A1/en active Pending
- 2021-12-14 IL IL303630A patent/IL303630A/en unknown
- 2021-12-14 JP JP2023536129A patent/JP2023554358A/ja active Pending
- 2021-12-14 TW TW110146777A patent/TW202237174A/zh unknown
- 2021-12-14 CA CA3199645A patent/CA3199645A1/en active Pending
- 2021-12-14 JP JP2023536126A patent/JP2024502720A/ja active Pending
- 2021-12-14 KR KR1020237023524A patent/KR20230118648A/ko active Search and Examination
- 2021-12-14 MX MX2023007064A patent/MX2023007064A/es unknown
- 2021-12-14 WO PCT/US2021/063235 patent/WO2022132712A1/en active Application Filing
- 2021-12-14 US US18/266,717 patent/US20240082363A1/en active Pending
- 2021-12-14 CN CN202180083941.4A patent/CN116710119A/zh active Pending
- 2021-12-14 CN CN202180083931.0A patent/CN116723852A/zh active Pending
- 2021-12-14 US US18/266,706 patent/US20240050532A1/en active Pending
- 2021-12-14 AU AU2021400816A patent/AU2021400816A1/en active Pending
- 2021-12-14 WO PCT/US2021/063231 patent/WO2022132709A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| IL303630A (en) | 2023-08-01 |
| EP4259186A1 (en) | 2023-10-18 |
| KR20230118936A (ko) | 2023-08-14 |
| US20240050532A1 (en) | 2024-02-15 |
| MX2023007064A (es) | 2023-07-31 |
| JP2023554358A (ja) | 2023-12-27 |
| JP2024502720A (ja) | 2024-01-23 |
| WO2022132709A1 (en) | 2022-06-23 |
| KR20230118648A (ko) | 2023-08-11 |
| EP4259185A1 (en) | 2023-10-18 |
| AU2021401635A1 (en) | 2023-06-22 |
| TW202237175A (zh) | 2022-10-01 |
| CN116710119A (zh) | 2023-09-05 |
| IL303631A (en) | 2023-08-01 |
| CA3199645A1 (en) | 2022-06-23 |
| TW202237174A (zh) | 2022-10-01 |
| CN116723852A (zh) | 2023-09-08 |
| AU2021400816A1 (en) | 2023-06-22 |
| CA3202345A1 (en) | 2022-06-23 |
| US20240082363A1 (en) | 2024-03-14 |
| WO2022132712A1 (en) | 2022-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007062A (es) | Metodos de tratamiento de la diabetes. | |
| EA202192327A1 (ru) | T-клеточные рецепторы, специфичные к mage-a4 | |
| Mu et al. | Pristimerin inhibits breast cancer cell migration by up-regulating regulator of G protein signaling 4 expression. | |
| Xu et al. | Anti-gastric cancer effect of melatonin and Bcl-2, Bax, p21 and p53 expression changes | |
| Van Warmerdam et al. | Clinical pharmacology of carboplatin administered in combination with paclitaxel. | |
| Augustin et al. | Effect of retinal coagulation status on oxidative metabolite and VEGF in 208 patients with proliferative diabetic retinopathy | |
| Plenchette et al. | NO and cancer: Itinerary of a double agent | |
| Ban et al. | Retrospective analysis of efficacy of trastuzumab in adjuvant treatment of HER 2 positive early breast cancer-single institution experience. | |
| Richter et al. | The prognostic significance of epidermal growth factor receptor expression in patients with anal carcinoma. | |
| Li et al. | Summary and expectation of the role of GnRHa in the treatment of breast cancer | |
| Liu et al. | Roles of curcumin combined with paclitaxel on growth inhibition and apoptosis of oral squamous cell carcinoma cell line CAL27 in vitro | |
| Arribas Del Amo et al. | Direct-to-implant breast reconstruction after neoadjuvant chemotherapy: A safe option? | |
| Ruan et al. | Outcome of childhood high-risk acute lymphoblastic leukemia treated with the ALL-BFM 95 protocol | |
| Xuan et al. | Sorafenib combined with chemotherapy and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation | |
| Ryoken | Prospective analysis of adverse reactions with long-term levofloxacin use | |
| Brančíková et al. | A case report: patient with advanced ovarial tumour and supporting care | |
| Liu et al. | Effect of psoralen on the stability after orthodontic tooth movement in rats | |
| Toyoda et al. | Timing of Administration of Pegfilgrastim and Prophylaxis for Febrile Neutropenia for Patients with Early Breast Cancer Receiving Chemotherapy | |
| Naito et al. | A case of unresected gastric cancer that maintained long tumor dormancy by use of paclitaxel+ S-1 combination therapy | |
| Yu et al. | Prognostic value of the number of lymph nodes retrieved after selective neck dissection in hypopharyngeal squamous carcinoma | |
| Kuznetsova et al. | Comparative study of immunomodulatory activity of peptides, tinrostim and thymalin | |
| Liu et al. | Clinical efficacy of sorafenib combined with low dose cytarabine for treating patients with FLT3+ relapsed and refractory acute myeloid leukemia | |
| Mochinaga et al. | Efficacy of aprepitant for quality of life of outpatients receiving moderately emetogenic chemotherapy | |
| Di Raimondo et al. | Management of multiple myeloma | |
| Kagawa et al. | Experience of Using Aflibercept Beta and FOLFIRI Chemotherapy for Metastatic Colorectal Cancer |